Literature DB >> 17488655

Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia.

Julius Juarez1, Rana Baraz, Shivashni Gaundar, Kenneth Bradstock, Linda Bendall.   

Abstract

BACKGROUND AND OBJECTIVES: The chemokine stroma-derived factor 1a (SDF-1a or CXCL12) is essential for proliferation of B lineage acute lymphoblastic leukemia (ALL) cells in their physiological microenvironment, bone marrow stroma. CXCL12 synergizes with cytokines that stimulate myeloid cells, but its interaction with cytokines affecting lymphoid cells has not been examined. We investigated whether interleukin (IL)-7 and IL-3 interact with CXCL12 to regulate ALL proliferation. DESIGN AND METHODS: The survival of ALL cells in serum-free cultures, with or without stromal support and cytokines, was assessed by flow cytometry, and proliferation by 3H-thymidine incorporation. Signaling mechanisms were assessed by western blotting of phosphorylated forms of signaling molecules and by the use of specific inhibitors.
RESULTS: CXCL12, IL-3, and IL-7 had only marginal effects on ALL cell survival under serum-free conditions. However, these molecules individually induced significant proliferative responses in stromal cultures of 11 cases of ALL. The combination of CXCL12 with IL-7 or IL-3 produced a variety of responses, with clear synergistic or additive interactions observed in four cases. Synergistic proliferation in response to CXCL12 plus IL-7 was associated with enhanced phosphorylation of the mitogen-activated protein kinases, ERK-1/2 and p38, and AKT, and was partially inhibited by pretreatment of cells with inhibitors for p38 MAPK and phosphatidylinositol 3-kinase, implicating these pathways in the proliferation in response to IL-7 plus CXCL12. INTERPRETATION AND
CONCLUSIONS: These findings indicate a complex interaction between signaling from the CXCR4 receptor on ALL cells with those initiated by the cytokines IL-7 and IL-3, suggesting that CXCL12 may facilitate ALL proliferation by enhancing cytokine-signaling pathways in responsive cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488655     DOI: 10.3324/haematol.10621

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  21 in total

1.  Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

Authors:  A Alsadeq; S Strube; S Krause; M Carlet; I Jeremias; C Vokuhl; S Loges; J A Aguirre-Ghiso; A Trauzold; G Cario; M Stanulla; M Schrappe; D M Schewe
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

2.  The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.

Authors:  Philip Saunders; Adam Cisterne; Jocelyn Weiss; Kenneth F Bradstock; Linda J Bendall
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

3.  Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.

Authors:  Rodrigo Jacamo; Ye Chen; Zhiqiang Wang; Wencai Ma; Min Zhang; Erika L Spaeth; Ying Wang; Venkata L Battula; Po Yee Mak; Katharina Schallmoser; Peter Ruvolo; Wendy D Schober; Elizabeth J Shpall; Martin H Nguyen; Dirk Strunk; Carlos E Bueso-Ramos; Sergej Konoplev; R Eric Davis; Marina Konopleva; Michael Andreeff
Journal:  Blood       Date:  2014-03-05       Impact factor: 22.113

Review 4.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 5.  Contribution of bone microenvironment to leukemogenesis and leukemia progression.

Authors:  F Ayala; R Dewar; M Kieran; R Kalluri
Journal:  Leukemia       Date:  2009-09-03       Impact factor: 11.528

6.  Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.

Authors:  Itaru Kato; Akira Niwa; Toshio Heike; Hisanori Fujino; Megumu K Saito; Katsutsugu Umeda; Hidefumi Hiramatsu; Mamoru Ito; Makiko Morita; Yoko Nishinaka; Souichi Adachi; Fumihiko Ishikawa; Tatsutoshi Nakahata
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

7.  Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: correlations with the course of disease.

Authors:  Ángeles Vicente López; Miriam Nohemí Vázquez García; Gustavo J Melen; Ana Entrena Martínez; Isabel Cubillo Moreno; Javier García-Castro; Manuel Ramírez Orellana; Agustín Gregorio Zapata González
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

Review 8.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04

9.  Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.

Authors:  Craig T Wallington-Beddoe; Anthony S Don; John Hewson; Qiao Qiao; Rachael A Papa; Richard B Lock; Kenneth F Bradstock; Linda J Bendall
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

10.  mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.

Authors:  Rana Baraz; Adam Cisterne; Philip O Saunders; John Hewson; Marilyn Thien; Jocelyn Weiss; Jordan Basnett; Kenneth F Bradstock; Linda J Bendall
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.